imiquimod has been researched along with Dyslipidemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W; Yang, C; Yang, W | 1 |
| Li, P; Li, X; Lin, Y; Liu, W; Wang, Y; Xie, X; Zhang, L | 1 |
2 other study(ies) available for imiquimod and Dyslipidemia
| Article | Year |
|---|---|
Knockdown of Bcl-3 alleviates psoriasis and dyslipidemia comorbidity by regulating Akt pathway.
Topics: Animals; Apolipoproteins E; Cholesterol; Comorbidity; Disease Models, Animal; Dyslipidemias; Glycogen Synthase Kinase 3 beta; Imiquimod; Leukemia, B-Cell; Mice; Mice, Inbred BALB C; NF-kappa B; Proto-Oncogene Proteins c-akt; Psoriasis; RNA, Small Interfering; Skin | 2022 |
Imiquimod induced ApoE-deficient mice might be a composite animal model for the study of psoriasis and dyslipideamia comorbidity.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Back; Cell Proliferation; Cholesterol; Comorbidity; Disease Models, Animal; Dyslipidemias; Imiquimod; Interleukin-17; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Psoriasis; Signal Transduction; Skin; STAT3 Transcription Factor | 2017 |